Observational studyRetina (Philadelphia, Pa.)2017
ACUTE CENTRAL SEROUS CHORIORETINOPATHY: Factors Influencing Episode Duration.
Observational study in Retina (Philadelphia, Pa.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.
- Interventions for central serous chorioretinopathy: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Effect of mindfulness-based stress reduction on acute central serous chorioretinopathy: a randomized control trial.International ophthalmology · 2024Trial
- Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Trial
- Structure-Function Correlation in Patients With Central Serous Chorioretinopathy During Initial Disease Activity and After Ten Years.Investigative ophthalmology & visual science · 2026Article
- Bilateral Chronic Central Serous Chorioretinopathy Leads to Macular Atrophy: A Case Report.Cureus · 2026Article
- Construction of a prediction model for the early efficacy of 577-nm-SML in treating CSC based on Bayesian network.BMC ophthalmology · 2026Article
- Treatment of central serous chorioretinopathy in comparison-microsecond-pulse laser versus photodynamic therapy.Die Ophthalmologie · 2026Review
- Radiomics-based fundus autofluorescence analysis in central serous chorioretinopathy-MICRoN report number twelve.Scientific reports · 2026Article
- Efficacy and safety of 577 nm subthreshold laser treatment in acute central serous chorioretinopathy.BMC ophthalmology · 2026Article
- Central Serous Chorioretinopathy: Etiology, Diagnosis, and Treatment.Deutsches Arzteblatt international · 2026Review
- Pachychoroid-Related Pigment Epithelial Detachment Treated with Photodynamic Therapy.Biomedicines · 2026Article
- Exploring retinal and choroidal characteristics on multimodal imaging in resolved central serous chorioretinopathy.Eye (London, England) · 2026Article
- Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study - MICRoN report number four.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Persistent Subretinal Fluid in a Case With Central Serous Chorioretinopathy and Progressive Retinal Changes: An 18-Month Longitudinal Case Report.Case reports in ophthalmological medicine · 2026Article
- Choroidal neovascularization as a trigger for central serous chorioretinopathy.International journal of retina and vitreous · 2025Article
- Exogenous Hormone Use as a Predictor of Central Serous Chorioretinopathy Recurrence: A Comparative Analysis of Observation Versus Low-Fluence Photodynamic Therapy.Journal of vitreoretinal diseases · 2025Article
- Prevalence of central serous chorioretinopathy in Denmark.Acta ophthalmologica · 2025Article
- [Letrozole-induced central serous chorioretinopathy].Die Ophthalmologie · 2025Article
- Treatment of central serous chorioretinopathy: new options for an old disease.Eye (London, England) · 2025Review
- Oscillatory photodynamic therapy in central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the influence of clinical and multimodal imaging parameters on the duration of acute central serous chorioretinopathy (CSCR) episodes.
methodsConsecutive patients with first, treatment-naïve central serous chorioretinopathy episodes presenting within 20 days of symptoms onset were prospectively included. They were reevaluated 15 days to 20 days later, followed by monthly evaluation for 6 months. Subfoveal choroidal thickness (SFCT), fluorescein leakage intensity on fluorescein angiography, elevation of retinal pigment epithelium (RPE) lesions at leakage sites, focal/multifocal pattern of indocyanine green angiography (ICGA) at baseline, time-dependent pattern of subretinal fluid (SRF) resorption on OCT using volume segmentation, history of corticosteroid intake and mean blood pressure were evaluated using univariate (Log rank test) and multivariate (Cox proportional hazard regression) survival analysis.
resultsThirty-one patients were included (26 men, 5 women, mean age: 40.0 ± 8.9 years, range: 24-58), of which 26 (84%) had episode resolution by 6 months. Using univariate analysis, episode duration was longer in cases with subfoveal choroidal thickness ≥500 μm (P = 0.0002), retinal pigment epithelium elevation at leakage sites ≥50 μm (P = 0.033), and a peak in subretinal fluid observed during follow-up (P = 0.013), and there was a near-significant association of intense fluorescein leakage (P = 0.074) with longer episodes. Using multivariate analysis, subfoveal choroidal thickness ≥500 μm (P = 0.017), retinal pigment epithelium elevation at leakage sites ≥50 μm (P = 0.010) and patient age ≥40 years (P = 0.010) were significantly and independently associated to longer episodes. Indocyanine green angiography pattern, corticosteroid intake, and blood pressure did not influence episode duration.
conclusionOlder age, higher subfoveal choroidal thickness, and higher degree of retinal pigment epithelium alteration at leakage sites are independent factors of longer acute central serous chorioretinopathy episodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.